Oral antihyperglycemic therapy for type 2 diabetes: Scientific review

JAMA

Volumn 287, Issue 3, 2002, Pages 360-372

  Inzucchi, Silvio E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT;

EID: 0037116638     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.3.360     Document Type: Review

References (154)

1. Diabetes in America: Epidemiology and scope of the problem
2. Prevalences of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly, bi-ethnic population
3. Emerging epidemic of type 2 diabetes in youth
4. The effects of treatment on the direct costs of diabetes
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
6. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
8. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: Problems and prospects
9. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: Prospective studies of Pima Indians
10. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: Evidence for a pathogenic role of relative hyperinsulinemia
11. Metabolic defects in lean nondiabetic offspring of NIDDM parents: A cross-sectional study
12. Obesity-independent hyperinsulinemia in nondiabetic first-degree relatives of individuals with type 2 diabetes
13. Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes
14. Natural history of macrovascular disease in type 2 diabetes: Role of insulin resistance
15. The cardiovascular dysmetabolic syndrome
16. Acute and chronic effects of hyperglycaemia on glucose metabolism: Implications for the development of new therapies
17. The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
18. Mechanism of free fatty acid-induced insulin resistance in humans
19. Free fatty acids and pathogenesis of type 2 diabetes mellitus
20. Standards of medical care for patients with diabetes mellitus
21. ACE consensus conference on guidelines for glycemic control
22. Translation of the diabetes nutrition recommendations for health care institutions
23. Commentary and translation: 1994 Nutrition recommendations for diabetes: Diabetes Care and Education, a practice group of the American Dietetic Association
24. Efficacy of glyburide in diabetics poorly controlled on first-generation oral hypoglycemics
25. Sulfonylureas
26. Diet and oral antidiabetic drugs and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus
27. Insulin resistance in noninsulin-dependent diabetes mellitus: Impact of sulfonylurea agents in vivo and in vitro
28. Mechanism of improvement in glucose metabolism after chronic glyburide therapy
29. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful
30. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control, insulin secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials: The Glipized Gastrointestinal Therapeutic System Study Group
31. Glimepiride, a new once-daily sulfonylurea: A double-blind placebo-controlled study of NIDDM patients
32. Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus
33. Diabetes control in the elderly: A randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus
34. Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: A multicenter, double-blind, randomized trial
35. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide: Glycemic control and insulin secretion during 15 months
36. Clinical evaluation of glimepiride versus glipizide in NIDDM in a double-blind comparative study: Glimepiride/Glyburide Research Group
37. Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus
38. Sulfonylureas and ischaemic preconditioning: A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide
39. Type 2 diabetes care: The role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention
40. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction
41. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, III: Clinical implications of UGDP results
42. The crux of the UGDP: Spurious results and biologically inappropriate data analysis
43. What is the benefit of increasing the sulfonylurea dose?
44. Metformin
45. The phenformin ban: Is the drug an imminent hazard?
46. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
47. Efficacy of metformin in the treatment of NIDDM: Meta-analysis
48. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
49. Mechanism by which metformin reduces glucose production in type 2 diabetes
50. Metformin: A review of its metabolic effects
51. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients
52. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: The Multicenter Metformin Study Group
53. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM
54. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: A study of two ethnic groups
55. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes
56. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial
57. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: The Essen-II Study
58. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
59. Efficacy of metformin in the treatment of NIDDM
60. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes
61. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus
62. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: A double-blind controlled study
63. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet
64. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO Study Group
65. Improved endothelial function with metformin in type 2 diabetes mellitus
66. Lactic acidosis in patients with diabetes treated with metformin
67. The U.K. prospective diabetes study: A review
68. The evolving role of alpha-glucosidase inhibitors
69. α-glucosidase inhibitors as agents in the treatment of diabetes
70. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone
71. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: A placebo-controlled double-blind study
72. Efficacy and safety of two different doses of acarbose in non-insulin-dependent diabetic patients treated by diet alone
73. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus
74. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: A multicenter controlled clinical trial
75. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM: A placebo-controlled dose-comparison study
76. Efficacy of acarbose monotherapy in patients with type 2 diabetes: A double-blind study conducted in general practice
77. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: Efficacy and safety of low and high doses
78. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition
79. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?
80. Effects of acarbose treatment in type 2 diabetic patients under dietary training: A multicentre, double-blind, placebo-controlled, 2-year study
81. Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus
82. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: The Essen Study
83. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone
84. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients
85. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program
86. Troglitazone-induced fulminant hepatic failure: Acute Liver Failure Study Group
87. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers
88. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects
89. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
90. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus
91. Mechanism of troglitazone action in type 2 diabetes
92. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
93. The hormone resistin links obesity to diabetes
94. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance
95. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes
96. Beta-cell mass dynamics in Zucker diabetic fatty rats: Rosiglitazone prevents the rise in net cell death
97. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
98. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study: The Troglitazone Study Group
99. The Rosiglitazone Clinical Trials Study Group: Once- and twice-dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes
100. The Rosiglitazone Clinical Trials Study Group: Rosiglitazone monotherapy is effective in patients with type 2 diabetes
101. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study: The Pioglitazone 001 Study Group
102. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
103. Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
104. Troglitazone in combination with sulfonylureas restores glycemic control in patients with type 2 diabetes: The Troglitazone Study Group
105. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
106. A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose-level lowering
107. Antidiabetic drugs present and future: Will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?
108. Nonhypoglycemic effects of thiazolidinediones
109. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
110. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects
111. Effects of troglitazone on atherogenic Jipoprotein phenotype in coronary patients with insulin resistance
112. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus
113. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects
114. Effect of pioglitazone on vascular reactivity in vivo and in vitro
115. Control of vascular cell proliferation and migration by PPAR-gamma: A new approach to the macrovascular complications of diabetes
116. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
117. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
118. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes
119. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study
120. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice
121. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes
122. Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin
123. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin
124. Review of prandial glucose regulation with repaglinide: A solution to the problem of hypoglycaemia in the treatment of type 2 diabetes?
125. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus
126. Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study
127. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes
128. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
129. Repaglinide versus glyburide: A one-year comparison trial
130. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas
131. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes: Dutch and German Repaglinide Study Group
132. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes
133. Repaglinide/troglitazone combination therapy: Improved glycemic control in type 2 diabetes
134. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes
135. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
136. Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity
137. Normal hepatic insulin sensitivity in lean, mild noninsulin-dependent diabetic patients
138. Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus
139. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus
140. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients
141. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: A randomized-multicentric trial in primary health-care: Diabetes and Acarbose Research Group
142. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes
143. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus: A model of medicine-based evidence
144. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44)
145. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: A randomized, placebo-controlled study
146. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics
147. Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphylurea therapy alone
148. Troglitazone in combination with sulphonylurea improves glycaemic control in type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone: Troglitazone Study Group
149. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors
150. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study: The Pioglitazone 027 Study Group
151. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients
152. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: A multicenter, randomized, double-blind, placebo-controlled trial
153. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes
154. Combining insulin and oral agents